查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085372

慢性特發性便秘治療市場：依療法、藥物類別、劑型、給藥途徑、處方狀態、最終用戶、通路和年齡層分類－2026-2032年全球市場預測

Chronic Idiopathic Constipation Therapeutic Market by Treatment Modality, Drug Class, Formulation Type, Route Of Administration, Prescription Status, End User, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，慢性特發性便秘治療市場規模將成長至 23.5 億美元，複合年成長率為 7.93%。

主要市場統計數據
基準年 2025 13.7億美元
預計年份：2026年 14.8億美元
預測年份：2032年 23.5億美元
複合年成長率 (%) 7.93%

慢性特發性便秘（CIC）是一種持續性疾病，其特徵是排便次數減少、排便困難、排便費力、大便乾結或排便不盡感等症狀，且無任何可識別的結構性、代謝性或藥物相關病因。 CIC 的定義是基於症狀標準（例如羅馬IV標準），並透過基於指南的臨床評估進行診斷。 CIC 是一種負擔沉重的胃腸道功能性疾病，會導致生活品質下降、工作效率降低、頻繁就醫以及長期服用非處方藥或處方藥。

慢性特發性便秘的治療架構是基於階梯式治療模式，首先是增加膳食纖維攝取、補充水分、進行體能活動和調整生活方式，然後使用非處方滲透性或刺激性瀉藥緩解症狀。對於這些治療效果不佳的患者，可合併使用氯離子通道活化劑（如魯比前列酮）、鳥苷酸環化酶C促效劑（如Linaclotide和Plecanatide） 、選擇性5-HT4促效劑（如普魯卡洛必利）或當地核准的慢性便秘治療藥物。人口老化、人們對腸腦功能障礙的認知不斷提高、胃腸病學服務覆蓋範圍擴大以及難治性便秘循證治療管道的加強，都促進了這種治療方法的廣泛應用。

CIC治療前景的變革性變化

慢性特發性便秘 (CIC) 的治療格局正從暫時緩解症狀轉向個人化、機制導向的治療。主要的胃腸病學會臨床指南日益強調，應根據症狀嚴重程度、先前治療反應、耐受性、合併症、安全性以及患者意願來制定治療方案。這強化了製劑在慢性特發性便秘治療中的作用，尤其適用於使用膳食纖維、聚乙二醇、乳果糖或刺激性瀉藥無法持續緩解症狀的患者。

人工智慧對CIC護理的累積影響

人工智慧 (AI) 正開始影響便秘相關性便秘 (CIC) 的治療生態系統，涵蓋藥物發現、臨床開發、診斷支持和病人參與等各個方面。 AI 驅動的分析可以幫助從臨床實驗室資料集中識別對治療有反應的亞組，模擬腸道動力和分泌通道，並協助尋找與目前歸類為特發性便秘表現型相關的生物標記。這些功能尤其重要，因為 CIC 具有高度異質性，並且可能與慢便秘、骨盆底功能障礙、藥物引起的併發症以及腸腦交互作用受損等重疊。

全球CIC治療市場的關鍵區域洞察

北美仍然是慢性特發性便秘治療市場最成熟的地區之一，這得益於其完善的診斷管道、廣泛的非處方藥和處方藥供應，以及基層醫療醫生和腸胃科醫生較高的認知度。在美國，種類繁多的已通過核准治療層級和充足的專科醫生資源促進了創新和品牌處方藥的普及。同時，加拿大的醫療保健以指南為基礎，其報銷決策也基於藥物清單，這會影響治療順序。

關於啟動CIC治療的關鍵群體特定見解

在東協，由於私人醫療保健體系的擴張、零售藥局網路的拓展以及人們對胃腸道疾病認知的提高，便秘治療的可及性正在改善。然而，處方藥的使用仍然高度依賴自付費用和保險報銷的差異。海灣合作理事會（GCC）市場憑藉其相對較高的醫療保健支出、專科醫生資源、對數位醫療的投資以及完善的慢性病管理體係等優勢，支撐著對品牌消化器官系統治療藥物的需求，前提是這些藥物的上市情況和患者的經濟能力能夠滿足需求。

影響 CIC 治療需求的關鍵國家特定見解。

美國是治療慢性特發性便秘的主要市場，這得益於其眾多經FDA已通過核准的特發性藥選擇、廣泛的非處方藥供應、較高的疾病認知度、較高的專科醫生就診率以及完善的階梯療法和預先核准流程。加拿大則採用較嚴格的報銷模式，由公私藥品目錄構成。同時，墨西哥和巴西也正受益於私人醫療保健、零售藥局管道、都市區醫療保健服務的普及以及人們對功能性腸道疾病日益成長的認知，推動了該領域的成長。

CIC治療領域領導者使用的實用建議

產業領導企業應優先考慮差異化的臨床證據，這些證據應包含除排便頻率以外的其他終點指標，例如排便用力、糞便性狀、腹脹、腹部不適、緊急用藥情況、治療滿意度和生活品質 (QOL)。真實世界證據 (RWE) 計畫可以透過展示治療的連續性、耐受性、醫療保健使用量的減少以及患者報告結局的改善（尤其適用於那些使用非處方藥 (OTC) 治療無法充分緩解症狀的患者），來加強與保險公司和臨床醫生的對話。

CIC治療分析調查方法

本執行摘要基於一項整合了來自監管機構、臨床實踐指南、同行評審的胃腸病學文獻、製劑資訊、藥物安全監測資源和市場進入資訊的公開證據的二級研究框架。資訊來源包括FDA和EMA等監管機構的監管資訊、專業學會的指導意見以及已發表的關於慢性便秘的流行病學、疾病負擔、治療途徑和治療結果的證據。

結論：CIC治療的策略展望

慢性特發性便秘 (CIC) 的治療格局正在從以傳統瀉藥為中心的治療模式，轉向更個人化、循證的治療模式，並輔以處方藥創新、患者報告結局以及數位醫療技術。隨著診斷技術的進步、人口老化以及臨床對功能性胃腸疾病的關注度不斷提高，預計已開發國家和新興國家醫療保健系統對有效 CIC 治療的需求將持續強勁。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：慢性特發性便秘治療市場：依治療方法分類

  • 非藥物療法/輔助性治療
  • 藥物治療

第8章：慢性特發性便秘治療市場：依藥物類別分類

  • 鳥苷酸環化酶C (GC-C)促效劑
  • 滲透性瀉藥
  • 刺激性瀉藥
  • 血清素 5-HT4 受體促效劑
  • 填充劑
  • 軟便劑

第9章：慢性特發性便秘治療市場：依劑型類型分類

  • 固態口服製劑
    • 藥片
    • 膠囊
  • 口服液體製劑
    • 解決方案
    • 懸浮液
  • 直腸準備
    • 栓劑
    • 灌腸

第10章：慢性特發性便秘治療市場：依給藥途徑分類

  • 直腸
  • 口服

第11章：慢性特發性便秘治療市場：依處方狀態分類

  • 非處方藥
  • 處方藥

第12章：慢性特發性便秘治療市場：以最終用戶分類

  • 醫院
  • 專科胃腸病診所
  • 基層醫療診所
  • 居家醫療
  • 長期照護機構
  • 復健中心

第13章：慢性特發性便秘治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：慢性特發性便秘治療市場：依年齡層分類

  • 兒童患者
  • 成年患者

第15章：慢性特發性便秘治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 慢性特發性便秘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 慢性特發性便秘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Albireo Pharma, Inc.（Ipsen SA）
  • ANI Pharmaceuticals, Inc.
  • Ardelyx Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • MSN Laboratories Private Limited
  • Norgine BV
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited
Product Code: MRR-4311CE1A3392

The Chronic Idiopathic Constipation Therapeutic Market is projected to grow by USD 2.35 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.37 billion
Estimated Year [2026] USD 1.48 billion
Forecast Year [2032] USD 2.35 billion
CAGR (%) 7.93%

Chronic idiopathic constipation (CIC) is a persistent disorder marked by infrequent bowel movements, difficult stool passage, straining, hard stools, or a sensation of incomplete evacuation without an identifiable structural, metabolic, or medication-related cause. Defined through symptom-based criteria such as Rome IV and evaluated through guideline-directed clinical assessment, CIC is a high-burden functional gastrointestinal disorder associated with impaired quality of life, reduced work productivity, recurring physician visits, and ongoing use of nonprescription and prescription therapies.

The chronic idiopathic constipation therapeutic landscape is anchored by a stepwise treatment model that begins with dietary fiber, hydration, physical activity, and lifestyle optimization, followed by over-the-counter osmotic and stimulant laxatives for symptom relief. For patients with inadequate response, prescription therapies include chloride channel activators such as lubiprostone, guanylate cyclase-C agonists such as linaclotide and plecanatide, selective 5-HT4 agonists such as prucalopride, and regionally approved agents used for chronic constipation. Adoption is supported by aging populations, improved recognition of disorders of gut-brain interaction, expanding gastroenterology access, and stronger use of evidence-based treatment pathways for refractory constipation.

Transformative Shifts in the CIC Therapeutics Landscape

The CIC treatment landscape is shifting from episodic symptom relief toward personalized, mechanism-based care. Clinical guidance from major gastroenterology societies increasingly emphasizes matching therapy to symptom severity, prior treatment response, tolerability, comorbidities, safety profile, and patient preferences. This has strengthened the role of prescription chronic idiopathic constipation therapies for patients who do not achieve sustained relief with fiber, polyethylene glycol, lactulose, or stimulant laxatives.

Commercial dynamics are also changing as payer scrutiny, generic availability, formulary management, and value-based access reshape prescribing behavior. At the same time, innovation is moving beyond complete spontaneous bowel movements alone toward abdominal symptoms, bloating, straining, stool consistency, rescue medication use, adherence, and patient-reported outcomes. Products and strategies that demonstrate durable efficacy, tolerability, convenient dosing, persistence, and real-world value are best positioned in the chronic idiopathic constipation therapeutic market.

Cumulative Impact of Artificial Intelligence on CIC Care

Artificial intelligence is beginning to influence the CIC therapeutic ecosystem across drug discovery, clinical development, diagnosis support, and patient engagement. AI-enabled analytics can help identify responder subgroups in clinical trial datasets, model gut motility and secretion pathways, and support biomarker exploration for constipation phenotypes currently classified as idiopathic. These capabilities are particularly relevant because CIC is heterogeneous and may overlap with slow-transit constipation, pelvic floor dysfunction, medication effects, and disorders of gut-brain interaction.

In clinical and commercial settings, AI can improve care pathways by analyzing electronic health records, pharmacy claims, symptom diaries, and patient-reported outcomes to detect inadequate treatment response earlier. Digital tools may help support escalation from OTC agents to prescription therapies, adherence monitoring, adverse event detection, and longitudinal symptom tracking. The cumulative impact is a gradual move toward precision gastroenterology, provided stakeholders address clinical validation, data privacy, algorithmic bias, interoperability, and regulatory expectations.

Key Regional Insights Across Global CIC Therapeutic Markets

North America remains one of the most mature regions for chronic idiopathic constipation therapeutics due to established diagnostic pathways, broad availability of OTC and prescription options, and high awareness among primary care clinicians and gastroenterologists. The United States supports innovation and branded prescription uptake through multiple approved therapeutic classes and strong specialist access, while Canada reflects guideline-driven care and formulary-led reimbursement decisions that influence treatment sequencing.

Europe shows steady demand supported by aging demographics, national health systems, and evidence-based gastroenterology practice, although reimbursement requirements and country-level access pathways vary across the region. Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia experience expanding health care access, aging populations, urban lifestyles, and broader recognition of functional gastrointestinal disorders. Japan is particularly notable for regional experience with constipation pharmacotherapy, including agents such as elobixibat for chronic constipation.

Latin America, the Middle East, and Africa present long-term opportunities tied to urbanization, retail pharmacy access, improved specialist availability, and rising awareness of chronic gastrointestinal symptoms. However, affordability constraints, underdiagnosis, uneven reimbursement, and differences in primary care referral pathways can limit adoption of premium prescription CIC therapeutics. Across these regions, clinician education, access to validated laxatives, better symptom recognition, and clear escalation protocols remain central to therapeutic development.

Key Group Insights for CIC Therapeutic Adoption

Within ASEAN, expanding private health care systems, growing retail pharmacy networks, and increasing gastroenterology awareness are improving access to constipation therapies, although prescription adoption remains sensitive to out-of-pocket spending and variable reimbursement. GCC markets benefit from comparatively strong health expenditure, specialist access, digital health investment, and chronic disease management infrastructure, supporting demand for branded gastrointestinal therapies where formulary coverage and patient affordability align.

The European Union provides a structured environment for clinical evidence generation, pharmacovigilance, regulatory oversight, and health technology assessment, making real-world effectiveness, safety, and cost-effectiveness important for chronic idiopathic constipation therapeutic access. BRICS countries offer significant patient reach and long-term adoption potential, led by China, India, and Brazil, but require localized pricing, distribution strength, physician education, and evidence packages aligned with public and private payer expectations.

G7 markets remain central for product launches, guideline influence, clinical research activity, and premium therapy adoption because of advanced regulatory systems, high treatment awareness, and mature gastroenterology networks. NATO member markets overlap substantially with North America and Europe, where regulatory alignment, pharmaceutical distribution capacity, supply chain resilience, and established health care infrastructure support dependable access to CIC therapeutics.

Key Country Insights Shaping CIC Therapeutic Demand

The United States is a leading country market for chronic idiopathic constipation therapeutics because of multiple FDA-approved prescription options, broad OTC availability, active disease awareness, high specialist utilization, and established payer processes for step therapy and prior authorization. Canada follows a more reimbursement-disciplined model shaped by public and private formularies, while Mexico and Brazil show growth through private care, retail pharmacy channels, urban health care access, and increasing recognition of functional bowel disorders.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging populations with guideline-oriented management of chronic constipation, although national reimbursement policies and prescribing rules shape the pace of branded therapy adoption. Russia maintains demand for constipation management, but access, affordability, and supply reliability remain important considerations for consistent availability of CIC therapeutics.

China and India offer substantial patient reach as diagnosis improves, urban populations seek care for chronic gastrointestinal symptoms, and hospital-based gastroenterology services expand. Japan and South Korea benefit from aging demographics, advanced health systems, and strong clinical awareness of chronic constipation, with Japan showing notable experience in regionally established constipation pharmacotherapy. Australia represents a developed, guideline-oriented market with strong primary care infrastructure, specialist referral networks, and access to both OTC and prescription treatment options.

Actionable Recommendations for CIC Therapeutic Leaders

Industry leaders should prioritize differentiated clinical evidence that goes beyond bowel movement frequency to include straining, stool consistency, bloating, abdominal discomfort, rescue medication use, treatment satisfaction, and quality-of-life endpoints. Real-world evidence programs can strengthen payer and clinician discussions by demonstrating persistence, tolerability, reduced health care utilization, and improved patient-reported outcomes among patients who do not achieve adequate relief with OTC therapy.

Organizations should localize market access strategies by aligning pricing, evidence packages, reimbursement submissions, and education initiatives with regional health system realities. Partnerships with gastroenterology societies, primary care networks, digital health platforms, and pharmacy channels can accelerate diagnosis, appropriate treatment escalation, and patient adherence. AI-enabled symptom tracking and adherence tools should be deployed only within validated clinical workflows supported by transparent data governance, privacy safeguards, and measurable patient benefit.

Research Methodology for the CIC Therapeutics Analysis

This executive summary is built on a secondary research framework that synthesizes publicly available evidence from regulatory agencies, clinical practice guidelines, peer-reviewed gastroenterology literature, prescribing information, pharmacovigilance resources, and market access intelligence. Sources include regulatory information from agencies such as the FDA and EMA, professional society guidance, and published evidence on chronic constipation epidemiology, disease burden, treatment pathways, and therapeutic outcomes.

The analysis applies triangulation across clinical, commercial, regional, group-level, and country-level indicators to identify durable strategic themes. Therapeutic classes and adoption dynamics were assessed through the lenses of disease burden, approved treatment availability, reimbursement environment, health care infrastructure, prescribing behavior, patient access, and barriers to escalation. Findings are presented as strategic industry insights and should not be interpreted as individual medical advice.

Conclusion: Strategic Outlook for CIC Therapeutics

The chronic idiopathic constipation therapeutic landscape is evolving from conventional laxative-centered management toward more personalized, evidence-based care supported by prescription innovation, patient-reported outcomes, and digital health capabilities. As diagnosis improves, populations age, and functional gastrointestinal disorders receive greater clinical attention, demand for effective CIC therapies is expected to remain resilient across developed and emerging health care systems.

Future leadership in chronic idiopathic constipation therapeutics will depend on clinical differentiation, access strategy, regional execution, and responsible use of AI to improve patient identification and treatment optimization. Organizations that combine strong evidence with affordability, physician education, pharmacy engagement, and patient-centered support will be well positioned to advance care and strengthen adoption in CIC therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Chronic Idiopathic Constipation Therapeutic Market, by Treatment Modality

  • 7.1. Non-Pharmacological / Adjunct
  • 7.2. Pharmacological

8. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class

  • 8.1. Guanylate Cyclase-C (GC-C) Agonists
  • 8.2. Osmotic Laxatives
  • 8.3. Stimulant Laxatives
  • 8.4. Serotonin 5-HT4 Receptor Agonists
  • 8.5. Bulking Agents
  • 8.6. Stool Softeners

9. Chronic Idiopathic Constipation Therapeutic Market, by Formulation Type

  • 9.1. Solid Oral Formulations
    • 9.1.1. Tablets
    • 9.1.2. Capsules
  • 9.2. Liquid Oral Formulations
    • 9.2.1. Solutions
    • 9.2.2. Suspensions
  • 9.3. Rectal Formulations
    • 9.3.1. Suppositories
    • 9.3.2. Enemas

10. Chronic Idiopathic Constipation Therapeutic Market, by Route Of Administration

  • 10.1. Rectal
  • 10.2. Oral

11. Chronic Idiopathic Constipation Therapeutic Market, by Prescription Status

  • 11.1. Over-the-Counter (OTC) Medicines
  • 11.2. Prescription Medicines

12. Chronic Idiopathic Constipation Therapeutic Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Gastroenterology Clinics
  • 12.3. Primary Care Clinics
  • 12.4. Home Care Settings
  • 12.5. Long Term Care Facilities
  • 12.6. Rehabilitation Centers

13. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Chronic Idiopathic Constipation Therapeutic Market, by Age Group

  • 14.1. Pediatric Patients
  • 14.2. Adult Patients

15. Chronic Idiopathic Constipation Therapeutic Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Chronic Idiopathic Constipation Therapeutic Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Chronic Idiopathic Constipation Therapeutic Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Albireo Pharma, Inc. by Ipsen S.A.
  • 19.3. ANI Pharmaceuticals, Inc.
  • 19.4. Ardelyx Inc.
  • 19.5. Bausch Health Companies Inc.
  • 19.6. Bayer AG
  • 19.7. Dr. Reddy's Laboratories Ltd.
  • 19.8. Eisai Co., Ltd.
  • 19.9. Ferring B.V.
  • 19.10. Ironwood Pharmaceuticals, Inc.
  • 19.11. Lupin Limited
  • 19.12. Mallinckrodt plc
  • 19.13. MSN Laboratories Private Limited
  • 19.14. Norgine B.V.
  • 19.15. Sanofi S.A.
  • 19.16. Shionogi & Co., Ltd.
  • 19.17. Takeda Pharmaceutical Company Limited
  • 19.18. Zydus Cadila Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BULKING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BULKING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BULKING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STOOL SOFTENERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STOOL SOFTENERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STOOL SOFTENERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUPPOSITORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUPPOSITORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUPPOSITORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENEMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENEMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENEMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKE